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ABSTRACT
Objective: Women with preeclampsia have elevated circulating levels of soluble fms-like 
tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve 
pregnancy outcome in animals with a preeclampsia-like syndrome. We investigated the 
effect of pravastatin on plasma sFlt-1 levels during preeclampsia.
Design: Blinded (clinician and participant), proof of principle, placebo-controlled trial
Setting: 15 UK maternity units.
Population: We used a minimization algorithm to assign 62 women with early-onset 
preeclampsia (24+0 - 31+6 weeks’ gestation) to receive pravastatin 40mg daily (n=30) or 
matched placebo (n=32), from randomization to childbirth. 
Primary outcome: Difference in mean plasma sFlt-1 levels over the first three days 
following randomization. 
Results: The difference in the mean maternal plasma sFlt-1 levels over the first three 
days after randomisation between the pravastatin (n=27) and placebo (n=29) groups was 
292pg/mL (95%CI: -1175- 592; p=0.5), and over days 1-14 was 48pg/ml (95% CI -1009 
to 913; p=0.9). Women who received pravastatin had a similar length of pregnancy 
following randomization compared with those who received placebo (Hazard ratio 0.84; 
95%CI: 0.50-1.40; p=0.6). The median time from randomization to childbirth was 9 days 
(IQR 5-14 days) for the pravastatin group and 7 days (IQR 4-11 days) for the placebo 
group. There were 3 perinatal deaths in the placebo-treated group and no deaths or 
serious adverse events attributable to pravastatin. 
Conclusions: 
We found no evidence that pravastatin lowered maternal plasma sFlt-1 levels once early 
onset preeclampsia had developed. Pravastatin appears to have no adverse perinatal 
effects.
Funding: Medical Research Council (G0701824)
Keywords: anti-angiogenic factor, double-blind, perinatal mortality, placebo-controlled, 
pravastatin, pre-eclampsia, randomized trial, statin.
Trial Registration: International Clinical Trial Registry Number: 23410175. 
www.isrctn.com/ISRCTN23410175A
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Tweetable abstract
Pravastatin does not improve maternal plasma sFlt-1 or PLGF levels following a 
diagnosis of early pre-term preeclampsia #clinicaltrial finds
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INTRODUCTION
Early-onset preeclampsia affects approximately 1:200 pregnancies and is associated with 
serious maternal and perinatal morbidity.1,2 In low resource nations, preeclampsia 
accounts for one in five of all maternal and perinatal deaths.3 No agents have yet been 
identified that can effectively treat preeclampsia, although low dose aspirin acts as a 
moderately effective prophylaxis.4,5 A more effective prophylaxis against preeclampsia 
and a targeted therapy are desperately needed. 
Preeclampsia is characterized by widespread endothelial dysfunction and is associated 
with loss of vascular endothelial growth factor (VEGF) activity. High circulating levels of 
soluble fms-like tyrosine kinase-1 (sFlt-1; also known as sVEGFR), the natural antagonist 
of VEGF,6 and low circulating levels of placental derived growth factor (PlGF), precede 
the onset of preeclampsia by several weeks.7, 8 Neutralization of excessive sFlt-1 by 
VEGF eliminates the signs of preeclampsia in cells9 and mice10 and extracorporeal 
removal of sFlt-1 in women with early-onset preeclampsia prolongs their pregnancy.11 
These observations support a role for angiogenic imbalance to the ‘preeclampsia 
phenotype’.
Statins inhibit sFlt-1 secretion from endothelial and trophoblast cells in vitro.12,13 Pregnant 
animals that over-express sFlt-1 from their placenta develop a preeclampsia like 
syndrome that is prevented by administration of pravastatin.14 We therefore propose 
statins as a novel therapy for the treatment of preeclampsia.12
Currently statins are contraindicated in both pregnancy and lactation by the British 
National Formulary (BNF) and the United States Food and Drug Administration (FDA). 
Statins taken during pregnancy, in particular lipophilic statins, that more readily cross 
plasma membranes, have been linked with major congenital malformations.15 Based on 
the scientific rationale that statins inhibit sFlt-1 from trophoblast and endothelial cells12 
and that below a critical threshold sFlt-1 fails to cause the signs of preeclampsia,10 we 
hypothesized that statins would ameliorate established preeclampsia. We reasoned that 
the potential benefit to a growth-restricted fetus of prolonging a preeclamptic pregnancy A
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between 24+0 - 31+6 weeks despite in utero exposure to a hydrophilic statin was in clinical 
equipoise with the potential harm of premature childbirth. There are currently no human 
data to support a minimum safe dose of pravastatin in pregnancy. As we were testing 
whether pravastatin offered a treatment effect in established early-onset preeclampsia, 
we chose pravastatin 40mg daily, the highest recommended daily dose of pravastatin 
outside of pregnancy. We therefore investigated whether pravastatin 40mg daily given to 
women with early-onset preeclampsia would reduce maternal plasma sFlt-1 levels and 
ameliorate their clinical condition. 
METHODS 
Trial design
We carried out the StAmP trial (Statins to Ameliorate Pre-Eclampsia), a double blind 
multicentre, placebo-controlled randomized trial in fifteen maternity units throughout the 
UK. All participants provided written informed consent before randomization.
Study Funding and Oversight
The study was funded by the Medical Research Council (G0701824) following a two-
stage peer review process.
Study oversight was provided by an independent Trial Steering Committee and an 
independent Data Monitoring Committee. Both committees reviewed accruing safety data 
during the period of recruitment on four occasions. Formal interim analysis was not 
undertaken. The Trial Steering Committee included a patient-parent representative from 
the Action on Pre-eclampsia charity.
Participants and Eligibility
Women over 18 years of age, who presented with preeclampsia between 24+0 and 31+6 
weeks’ of gestation, with a single viable fetus and no major anomalies were eligible for 
inclusion. Preeclampsia was defined by new-onset hypertension (>90mmHg diastolic) 
and new-onset proteinuria at 2+ on standard urinary dipstick, confirmed by a spot 
protein:creatinine ratio (PCR) >30mg/mmol or >300mg total protein in a 24-hour urine 
sample. Women with preeclampsia superimposed on chronic hypertension were also 
eligible.16 Women were excluded if the attending clinician considered it unlikely that the A
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pregnancy would continue for more than 48 hours after the diagnosis of preeclampsia, or 
were already taking statins, or had contraindications to statins. 
Randomization and study interventions
Eligible, consenting women were randomized in a 1:1 ratio by a secure telephone or web-
based central randomization service at the University of Birmingham Clinical Trials Unit, 
whereupon the trial drug pack number was not revealed until all eligibility criteria 
confirmed and the patient committed to the trial. Participants were randomised to receive 
either daily Pravastatin (40mg) or placebo of identical appearance, as a fixed dose. Trial 
drug was taken each evening until childbirth. Neither the clinician nor the participant were 
aware of the trial drug allocation. Women were expected to remain as in-patients, 
according to current guidelines.17 Later in the study, women with stable preeclampsia 
could be managed as outpatients. 
A computerized minimized randomization procedure was used to achieve balance 
between groups for gestational age at diagnosis (<30 weeks, ≥30+0 weeks), smoking 
status (current, stopped once pregnant, never smoked) and severity of hypertension 
(moderate hypertension >140mmHg and <160mmHg systolic, or >90mmHg and 
<110mmHg diastolic; severe hypertension ≥160mmHg systolic or ≥110mmHg diastolic) 
and by centre.
Maternal outcome measures 
The primary outcome was the mean maternal serum sFlt-1 levels during the first 3 days 
post randomization. Secondary anti-angiogenic outcomes were serum concentration of 
sFlt-1 and the sFlt-1:PIGF ratio over the first 14 days post-randomization and during the 
remainder of pregnancy. The main secondary clinical outcome was time from 
randomization to childbirth. Indicators of preeclampsia severity were blood pressure, 
proteinuria, serum levels of creatinine, uric acid, albumin, liver transaminases, 
electrolytes, platelets, and those of maternal status were prothrombin time, C-reactive 
protein, haemoglobin and bilirubin. 
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Following recruitment, fetal wellbeing was assessed using cardiotocography, umbilical 
artery blood flow and amniotic fluid volume. All outcomes were considered over the first 3 
days post-randomization, over 14 days and during the whole of the pregnancy. Outcomes 
were censored at the time of delivery.
Blood and urine samples were collected immediately before randomization, daily for the 
first three days post-randomization, then twice a week until the mother was discharged 
from hospital post-partum. Final samples were taken 6 weeks’ post-partum. All 
biochemical parameters except s-Flt-1 and PIGF were measured locally using routine 
assays. An additional sample of plasma was stored locally at -80°C until the women’s 
completion of the trial, whereupon all her samples were transferred to a central 
laboratory. Soluble Flt-1 and PIGF were measured in a single batch-analysis using the 
BRAHMS Kryptor system (Thermo Fisher Scientific Inc, Germany). 
Neonatal outcome measures
At birth, offspring weight, Apgar scores at 1 and 5 minutes and incidence of neonatal 
complications of prematurity were collected. When possible, paired maternal and 
umbilical cord blood was collected at childbirth for central batch quantification of 
Pravastatin and Pravastatin lactone using a Shimadzu Nexera XR HPLC analyzer.
Adverse events were reported by participating clinicians and were reviewed by the data 
monitoring committee. These were categorized under UK regulatory reporting 
requirements as serious adverse reactions if they resulted in maternal or fetal death or 
threatened the life of mother or baby, or resulted in a longer than anticipated post-natal 
maternal admission and were considered causally related to the study treatment, and 
classed as unexpected if not within the known side effect profile of pravastatin.
Outcomes were selected before the development of a core outcome set for pre-
eclampsia.
Other management of preeclampsia and timing of childbirth
Management of preeclampsia was directed by UK guidelines for management of 
hypertension in pregnancy.17 Dexamethasone or Betamethasone, was given to reduce A
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the risk of neonatal respiratory distress syndrome, according to the risk of imminent 
childbirth. The indication for childbirth was left to the judgement of individual clinicians 
managing preeclampsia according to UK National Institute of Health and Care Excellence 
guidelines.17 Drivers for childbirth included uncontrollable hypertension 
(BP≥170/110mmHg), worsening maternal blood profile, a non-reassuring 
cardiotocograph and reversed end diastolic flow in the umbilical artery. 
Statistical Analysis
According to preliminary work, we assumed the plasma level of sFlt-1 in a preeclampsia 
population to be approximately 6700 pg/ml.7 To detect a one standard deviation reduction 
from this level (around 2100 pg/ml) with 80% power (p=0.05) and assumed correlations 
of 0.9 (for days 1-3 measurements) and 0.1 (between baseline and post) would require 
32 participants. To allow for some missing data and to increase our ability to detect 
difference in pre-specified subgroups the sample size was inflated to 128 participants in 
total. This target was later revised to 64 participants given the challenges of recruiting 
participants into the trial. Our ambition to undertake subgroup analyses was therefore 
abandoned but the other assumptions around the sample size calculation remained the 
same.
.
Primary analyses were by intention-to-treat. Continuous measures (including the primary 
outcome and other biochemical parameters) were compared with the use of multilevel 
repeated measures models,18 including parameters for group, time and baseline values. 
No evidence was found of any time by treatment interaction so a constant treatment 
effect over time was assumed in these analyses. sFlt-1, PlGF and the ratio sFlt-1:PLGF 
were also analysed following log transformation to account for any possibility of skewed 
distribution. Kaplan-Meier plots were constructed for time from randomization to 
childbirth; a Cox proportional hazards model was used to calculate hazard ratios. Per 
protocol analyses were performed to explore the effect of compliance including only 
those participants who remained on allocated intervention for at least three days before 
delivery.
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Exploratory post-hoc analyses investigated if a number of potentially prognostic 
variables, collected before randomization as part of the trial, had any relationship with 
time to delivery. The following variables (all measured on a continuous scale) were 
considered together in a multivariable Cox Proportional Hazard model with time delivery 
as the outcome: a) gestational age at diagnosis; b) systolic blood pressure; c) diastolic 
blood pressure; d) PlGF; e) sFlt-1; f) proteinuria/ 24 hours; g) uric acid h) platelets. In 
addition, i) sFlt-1/PlGF ratio was also assessed but as a replacement for d) and e). 
Where calculated, effect sizes are presented with 95% confidence intervals and p-values 
from two-sided tests. SAS software, version 9.4 (SAS Institute), was used for analyses.
RESULTS
Patients and follow-up
Between June 2011 and June 2014, 62 participants with early onset preeclampsia (24-
31+6 weeks gestation) were randomized from 15 UK maternity units. Due to slowing 
recruitment rates after 33 months, we agreed with the Trial Steering Committee to set an 
end date of 3 years after trial start, irrespective of our target of 64 participants. 
Presenting clinical features of preeclampsia, recorded before randomization, were 
comparable between both groups (Table 1 and Table S1). There were no maternal 
deaths. All 30 infants born to mothers who received pravastatin survived, whereas 29/32 
infants from women who received placebo survived (Figure 1).
Compliance
Twenty-one women in each group received daily study drug until childbirth. A further four 
participants in the pravastatin group and one in the placebo group received at least three 
days of study drug, but stopped taking the drug two or more days before childbirth 
(Figure 1). Anti-hypertensive medication was taken by 60/62 women until childbirth.
Primary and biomarker outcomes
Maternal plasma levels of  sFlt-1 were lower in the pravastatin group compared with 
placebo, although differences were small and not statistically different over days 1-3 (292 A
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pg/ml (95% CI -1175 lower to 592 higher; p=0.5) and days 1-14 (48pg/ml (95% CI -1009 
to 913; p=0.9) (Figure 2A). No differences between groups were found for maternal 
plasma PlGF levels nor for  the sFlt-1:PIGF ratio (Figures 2B and 2C, Table 2, Table S2). 
There were no differences in sFlt-1 or sFlt-1:PlGF ratio between groups post-partum 
(Figure S1). Before randomization, women with preeclampsia who received pravastatin 
had lower serum sFlt-1 levels compared with those who received placebo but this 
difference did not reach statistical significance. Per protocol analyses and sensitivity 
analyses produced comparable results for each comparison (Figure S2).
Clinical outcomes
On average, pravastatin prolonged the pre-eclamptic pregnancy compared with placebo 
(hazard ratio 0.84; 95%CI: 0.50 to 1.40) but this difference was not significant (p=0.6). 
The median time from randomization to childbirth was 9 days (IQR 5-14 days) for women 
in the pravastatin group and 7 days (IQR 4-11 days) for the placebo group. (Figure S3). 
Women who received pravastatin for 3 or more days as per protocol, continued their 
pregnancy for 11 days (IQR 6-14 days) compared with 7 days (IQR 6-11 days) for those 
who received placebo (HR: 0.76; 95%CI 0.41 to 1.42; p=0.4) (Figure S4).
Maternal blood pressure and all biochemical parameters were similar between the groups 
over the first 3 days and up to day 14 (Table 2, Table S3). Markers of fetal growth and 
wellbeing, including umbilical artery pulsitility index, did not differ between groups (Table 
S4).
Maternal and fetal reasons for childbirth are shown in Table S5. A clinical decision to 
deliver the baby in response to deteriorating maternal or neonatal status was made for 29 
women in the pravastatin group and 30 women in the placebo group. Other than a single 
participant in the placebo group, all deliveries were by caesarean section. There were no 
perinatal deaths in the pravastatin group, but 3 perinatal deaths in the placebo group. 
One baby died in utero at 26+4 weeks, another born at 26 weeks’ died on day 8 from 
sepsis and a third neonate, born at 24+6 weeks’ gestation, died on day 2 following 
massive pulmonary haemorrhage. A
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Amongst the surviving infants, mean birth weight was 1.1kg (SD 0.6) and 1.1kg (SD 0.5) 
for babies born to mothers in the pravastatin and placebo groups, respectively). Neonatal 
Apgar scores were also comparable. Adverse outcomes associated with prematurity 
were generally comparable. However, a higher proportion of babies developed 
necrotizing enterocolitis in the placebo group (n=6; 20%) compared with pravastatin 
group (n=3; 10%). Likewise, retinopathy of prematurity was more common in the placebo 
group (n=8; 28%) compared with pravastatin group (n=4; 13%; Table S6). 
By 6 weeks post-partum, maternal blood pressure had returned to normal in both groups 
(pravastatin group mean blood pressure 128.1mmHg (SD 18.2)/80.4mmHg (SD 13.0); 
placebo group mean blood pressure 128.0mmHg (SD 13.0)/79.4mmHg (SD 11.4). 
Similarly, biochemical parameters had also returned to normal in both groups. (Table S7).
Adverse events
There were no serious adverse reactions considered attributable to study treatments. 
Serious adverse events considered unrelated to the treatment were reported in 5 women 
in the pravastatin group, (2 emergency deliveries for severe hypertension, one 
antepartum haemorrhage, one mother was readmitted post-partum with hypertension and 
one women who experienced post-partum psychosis. In the placebo group one women 
had an antepartum fever requiring hospitalization, one had a post-partum hematoma at 
the surgical site and three required emergency delivery due to progressive preeclampsia 
(Tables S5 and S6). Non-severe adverse events were indistinguishable from symptoms 
of preeclampsia e.g. headache, and nausea.
Predictors of time to delivery
Of the variables investigated, only PlGF (HR: 0.97; 95%CI 0.94 – 1.00, p=0.03) and the 
sFlt-1/PlGF ratio (HR: 1.33; 95%CI 1.12 – 1.57, p=0.0009) were significantly associated 
with time from randomization to delivery, (Table S8). Results were robust to sensitivity 
analyses (Table S9 and S10).
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Maternal transfer of pravastatin
At the time of childbirth, paired maternal and umbilical cord blood samples were available 
for 18 participants in the pravastatin group and 16 in the placebo group. There was wide 
variability in the period between drug intake and blood collection to detect pravastatin. 
Women in the pravastatin treated group had plasma pravastatin levels (mean 0.86ng/ml 
SD 0.58) and fetal cord blood levels (mean 0.84ng/ml SD 1.05), which are both at the 
estimated assay limit for detectability for pravastatin (0.89ng/ml). Women in the placebo 
group and their fetus, had circulating pravastatin levels well below the limit of 
detectability. (Table S11) We attempted to measure pravastatin lactone levels but the 
assay was unstable and could not be validated. 
DISCUSSION
Main Findings
In this first randomized, placebo controlled doubled blind trial of pravastatin to ameliorate 
early onset preeclampsia, we found no difference in maternal plasma sFlt-1 
concentration, or s-Flt-1:PIGF ratio between women who took pravastatin or placebo. 
Whether pravastatin 40 mg daily for 3 days was insufficient to reduce sFlt-1 levels in 
women with established early-onset preeclampsia or reflects genuine therapeutic 
inefficacy remains uncertain. It is possible that pravastatin given as a prophylaxsis to 
women at risk of preeclampsia to womenmay improve the angiogenic profile and delay 
the clinical onset of the condition. 
We showed that women with preeclampsia who received pravastatin prolonged their 
pregnancy by up to 4 days on average. Four days is a meaningful length of time for a 
fetus <32 weeks to mature,19 but we cannot rule out that this effect may have occurred by 
chance. Furthermore, preeclamptic women who received pravastatin had a lower 
baseline sFlt-1:PlGF ratio compared with women who received placebo. Others have 
shown that a high sFlt-1:PIGF ratio is associated with an increased adverse outcome and 
shortened time to delivery.20 Our own exploratory analyses confirmed this association, 
which could explain the slightly longer pregnancy duration following pravastatin 
treatment. When we adjusted for this baseline imbalance in sFlt-1:PlGF ratio then the A
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hazard ratio for time to delivery moved to 1.07 (95%CI: 0.61-1.88) from 0.84 (95%CI: 
0.50 to 1.40), although the uncertainty is such that either estimate could still not rule out 
benefit or harm.
We found no evidence that pravastatin had a significant impact on other maternal clinical 
parameters of preeclampsia. Six weeks after childbirth, all mothers in both groups had 
made a full clinical recovery from preeclampsia. 
Adverse neonatal outcomes appeared to be less common in women who received 
pravastatin. None of the adverse neonatal outcomes were unexpected for neonates born 
as a consequence of extreme early-onset preeclampsia and differences may have 
occurred by chance. Our trial supports the safety of maternal pravastatin in a larger trial 
of women with preeclampsia or at risk of preeclampsia to improve maternal and neonatal 
outcomes. 
Strengths and Limitations
The Stamp trial benefited from strictly concealed randomization and double-blinded drug 
administration across a number of sites. Recruitment was challenging, at an average of 
1.4 participants per hospital per year, and the trial finished with two participants less than 
the revised target. The main reasons for slow recruitment were the low incidence of early-
onset preeclampsia, rapid clinical deterioration and the inability to gain informed consent 
to a trial of a drug that remains contraindicated in pregnancy. Greater patient and parent 
involvement potentially may have improved the recruitment process. The chief clinical 
investigator’s hospital,recruited 19/62 (31%) of study participants. 
The assumption that we might observe a one standard deviation reduction in sFlt-1 over 
days 1-3 – equivalent to a large difference21 - may have been overoptimistic and could 
have diminished our ability to detect a difference between the groups.
Participants had early-onset preeclampsia according to clear and recognized criteria, 
although two women who had extended gestation after inclusion (one from each group) 
may have had gestational proteinuria and transient hypertension at presentation. Despite 
all participants initially managed as inpatients, compliance with the drug regime was A
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lower than expected, although per protocol analyses did not suggest this had any impact 
on the conclusions. The decision to deliver the baby was the prerogative of the attending 
clinician, and we found the predominant reasons for delivery were related to deterioration 
in the fetal condition, which did not vary substantially between groups. The timing of cord 
blood venesection in relation to the last dose of pravastatin was not noted, which may 
explain why drug concentrations were around the lower limit of detection for the assay.
Interpretation
Before the clinical onset of pre-eclampsia there is a gradual rise in sFlt-1 levels8. Three 
weeks before the onset of hypertension and proteinuria, women have serum sFlt-1 levels 
that are 1200pg/ml lower than at the time of diagnosis with pre-eclampsia.8 Furthermore, 
women with the highest mean arterial blood pressure in early pregnancy developed pre-
eclampsia with lower levels of sFlt-1 levels7. In the Stamp trial, we could not rule out the 
possibility that pravastatin reduced plasma sFlt-1 levels by as much as 1175pg/mL. It is 
possible that this size of sFlt-1 reduction could moderate the clinical signs of pre-
eclampsia and usefully prolong pregnancy for the benefit of fetal maturity. This possibility 
requires further investigation in a larger study.
One open-label trial investigated the effects of pravastatin 20mg daily on pregnant 
women with antiphospholipid antibody syndrome (APS) who developed preeclampsia 
between 21-30 weeks.22 In contrast to an additional 9 (IQR 5-14) days of pregnancy in 
our pravastatin-treated group, these investigators found that pravastatin prolonged a 
preeclamptic pregnancy by a median 13 weeks (IQR 10-15 weeks). Their 10 pravastatin-
treated women gave birth at a median 36 weeks’ gestation (IQR 35-36) and all offspring 
survived. Eleven further women with APS and preeclampsia did not receive pravastatin 
and continued their pregnancies for a median 4.5 weeks (IQR 2-6 weeks). These women 
gave birth at a median 26.3 (IQR 26-32) weeks gestation and only 5 infants survived.22 It 
is possible that pravastatin is particularly effective at ameliorating preeclampsia in women 
with APS. However, the non-pravastatin treated group continued their pregnancies for a 
further 4.5 weeks, whereas most large observational studies of early-onset preeclampsia 
find that expectant management prolongs pregnancy for a further 7-10 days,23 similar to 
the 7 (IQR 4-11) days in the placebo group of our own study. A
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A pharmacokinetic study in which pravastatin 10 mg daily was administered from the 
beginning of the second trimester (12+0 - 16+6 weeks/gestation) to 11 women with 
previous early-onset preeclampsia resulted in a non-significant reduction in sFlt-1 levels 
compared with 10 women who received placebo.24 Similar to our study, this 
pharmacokinetic study found that the majority of pravastatin levels for maternal and 
umbilical cord samples were below the limit of quantification.24 As pravastatin has a half-
life of 1.8 hours and reaches peak plasma levels around 26.5ng/mL at 1 to 1.5 hours post 
oral dose, the low levels of pravastatin in maternal and cord blood, could be explained by 
a prolonged period of up to 24 hours from the last dose of pravastatin until childbirth. We 
found similar low plasma pravastatin levels in mother and fetal cord blood, which 
suggests transplacental passage despite the hydrophilic nature of pravastatin. However, 
in the study of 11 women who received pravastatin 10mg daily from early in the second 
trimester, fetal cord blood cholesterol levels at childbirth were unaltered.24
National pharmacopoeias still recommend that statins are avoided during pregnancy due 
to concerns about congenital anomalies and long term effects on fetal development. 
However, concerns about first trimester statin exposure have receded since the 
observation that major congenital malformations were no more common in the offspring 
of 1152 statin-exposed pregnant women after adjusting for pre-existing diabetes.25 
Concerns about the effect of statin use throughout pregnancy on long-term childhood 
development remain.
Statins have pleiotropic effects beyond their beneficial effects on angiogenic factors in 
vitro and in animal studies.26 It remains to be investigated whether earlier use of statins 
might prevent or delay the onset of preeclampsia and whether pathways other than 
rebalancing an unfavourable angiogenic profile might be causative. Furthermore, statins 
are recommended for the primary prevention of cardiovascular disease,27 a condition to 
which women with preeclampsia are predisposed.28
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Conclusions
Pravastatin 40mg daily was well tolerated by women with early onset preeclampsia and 
had no detectable adverse effects on the short-term health of offspring. When given after 
the clinical diagnosis of preeclampsia, we could find no evidence that pravastatin was 
effective in overcoming the relentless progression of the established condition. There 
may be a role for statins to prevent preeclampsia in women at high risk but this remains 
unexplored.  
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Table 1 Characteristics of randomized women.
There were no significant difference between groups in any of these characteristics
Pravastatin 
(n=30)
Placebo (n=32)
<20 0 (-) 1 (3%)
20-29 8 (27%) 13 (41%)
30-39 18 (60%) 15 (47%)
≥40 4 (13%) 3 (9%)
Age (years)
Mean (SD) 32.4 (5.6) 30.4 (6.3)
White 13 (43%) 17 (53%)
Mixed 1 (3%) 2 (6%)
Asian 5 (17%) 7 (22%)
Black 10 (33%) 5 (16%)
Ethnicity
Chinese 1 (3%) 1 (3%)
Smoker 2 (7%) 1 (3%)
Stopped when became pregnant 1 (3%) 1 (3%)
Smoking status at 
diagnosis A
Non-smoker 27 (90%) 30 (94%)
<30 weeks 23 (77%) 24 (75%)
≥30 weeks 7 (23%) 8 (25%)
Gestational age at 
diagnosis A Mean (SD) (weeks+days) 28+1 (2+0) 27+6 (2+2)
1 12 (40%) 18 (56%)
2 6 (20%) 6 (19%)
3 5 (17%) 4 (13%)
4 4 (13%) 1 (3%)
Gravida
>=5 3 (10%) 3 (9%)
0 19 (63%) 25 (78%)
1 2 (7%) 0 (-)
2 3 (10%) 4 (13%)
3 5 (17%) 0 (-)
Parity
>=4 1 (3%) 3 (9%)
Mean (SD) 29.7 (7.0) 29.6 (6.5)BMI (kg/m2)
Missing 3 (10%) 2 (6%)
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Mild
>140mmHg systolic or 
90mmHg diastolic but 
<160mmHg and 
<110mmHg respectively
13 (43%) 14 (44%)
Severity of preeclampsia A
Severe
≥160mmHg systolic or 
110mmHg diastolic
17 (57%) 18 (56%)
A Stratification variable and pre-defined sub-group
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Table 2 Angiogenic biomarkers and other parameters of preeclampsia severity in the antepartum period - intention to treat analysis.
sFLT-1 Soluble FMS-like tyrosine kinase-1; PIGF Placental derived growth factor
Baseline
Mean (SD)
Days 1-3A
Mean (standard 
deviation)
Days 4-7A
Mean (standard 
deviation)
Days 8-14A
Mean (standard 
deviation)
Days 15-21A
Mean (standard 
deviation)
Days 22-28A
Mean (standard 
deviation)
Difference 
over days 1 – 
3B,D
Estimate 
(95% CI)
Difference 
over days 1 – 
14C,D
Estimate (95% 
CI)
Pravastati
n
Placebo Pravastati
n
Placebo Pravastati
n
Placebo Pravastati
n
Placebo Pravastati
n
Placebo Pravastati
n
Placebo
sFLT-1 
(pg/mL)
N=29     
8296 
(5046)
N=31 
11065 
(6665)
N=27     
8516 
(4795)
N=29    
12241 
(6390)
N=19     
9210 
(5037)
N=19 
10609 
(5367)
N=15     
7518 
(5837)
N=10 8132 
(4050)
N=5     
12811 
(8937)
N=4   8458 
(4109)
N=1         
1293 (-)
N=3   
12205 
(10341)
-292 (-1175 , 
592) p=0.5
-49 (-1010, 
913) p=0.9
PlGF (pg/mL) N=29  
23.53 
(46.60)
N=31 
20.37 
(40.33)
N=27  
37.17 
(121.40)
N=29    
18.67 
(35.27)
N=20  
15.98 
(13.04)
N=19 
25.39 
(59.77)
N=15  
57.56 
(177.53)
N=10 
36.13 
(89.51)
N=5     
82.13 
(150.63)
N=4 40.15 
(39.81)
N=1  
528.60 (-)
N=3 43.84 
(58.80)
8.94 (-13.33,  
31.20) p=0.4
8.77 (-11.61, 
29.15) p=0.4
sFLT-1/PIGF N=29  979 
(1076)
N=31 1782  
(1697)
N=27  947  
(884)e
N=29     
2012 
(1779)e
N=19  
1078  
(940)
N=19 1747 
(1388)
N=15  958  
(793)
N=10 1479 
(1228)
N=5 1557 
(2118)
N=4 653 
(756)
N=1    2 (-) N=3 2361 
(3696)
-37 (-364, 
291) p=0.8
-54 (-364, 255) 
p=0.7
Blood 
pressure 
(systolic/ 
N=30  
159.9  
(15.6)/
N=32 
167.1  
(18.3)/99.
N=29  
146.6 
(16.3)/
N=31 
145.4(11.8
)/ 89.4  
N= 24 
140.8  
(8.9)/
N=24 
146.9 
(11.8)/ 
N=16  
145.3  
(11.8)/
N=13 
147.0  
(15.3)/ 
N=5     
137.1 
(17.8)/
N= 5 138.6  
(8.2)/ 84.7 
(9.4)
N=1    
135.5 (-)/ 
75.8 (-)
N=4 151.2 
(22.6)/ 
91.2  
Systolic -1.4 (-
8.6, 5.7) 
Diastolic -1.0 
Systolic -0.5 (-
6.0, 5.0) 
Diastolic -2.0 
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 A Mean is taken for each patient with any daily value available in the respective time period. The group mean and standard deviation is then generated from these means. 
B Mean difference and 95% confidence interval taken from a repeated measures analysis incorporating values taken on days 1-3, adjusting for baseline score. 
C Mean difference and 95% confidence interval taken from a repeated measures analysis incorporating values taken on days 1-14, adjusting for baseline score.
D Negative mean differences suggest biochemical parameter in the pravastatin group is generally lower than in the placebo group.
diastolic 
mmHg)
97.9 (5.4) 6  (6.9) 88.4  (9.9) (5.9) 85.7 (8.8) 91.2  (9.8) 88.1  (9.4) 88.2  
(11.3)
85.6 (12.7) (13.2) (-5.0, 3.1) (-5.9, 1.9)
24hour 
urinary 
protein 
(g/24hr)
N=14
1.81  
(4.24)
N=10
 2.97 
(3.18)
N=10
1.23 (1.09)
N=5
3.78 (3.89)
N=3
1.11 (0.84)
N=2
6.66 (0.29)
N=4
3.37 (3.64)
N=2
12.42 
(7.86)
N=2
4.34 (3.30)
N=1
9.90 (-)
N=1
0.37 (-)
N=2
0.58 (0.56) 0.58 (0.18, 
0.99)
-1.17 (-3.65, 
1.01)
Urinary 
protein: 
creatine ratio 
(mg/mmol)
N=28
3.34 (3.92)
N=32
4.06 (4.69)
N=22
3.87 (5.10)
N=27
5.56 (5.82)
N=16
6.86 (8.85)
N=17
7.82 (7.48)
N=9
7.73 (5.28)
N=10
8.54 (7.91)
N=4
8.04 (2.25)
N=3
1.89 (2.88)
N=0
- (-)
N=3
3.63 (4.56) -0.82 (-2.90. 
1.26)
-0.87 (-3.30, 
1.55)
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Figure 1 Patient flow through the StAmP Trial.
Compliance categorization:
Complete: took study drug all days before delivery or ceased on day of delivery
Partial: stopped taking study drug before delivery, or took study drug intermittently, but took study drug 
on days 1-3 from randomization
Poor: took study drug for 0-2 days but pregnancy maintained ≥ 3days
Rapid delivery: took study drug for 0-2 days, pregnancy ended by day 3. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Figure 2 Repeated measures analysis of s-FLT-1, PlGF and sFLT-1: PIGF during pregnancy and post-
randomization, intention to treat analysis.
A: Soluble FMS-like tyrosine kinase-1 (sFlt-1)
B: Placental-derived growth factor (PlGF)
C: Ratio Soluble FMS-like tyrosine kinase-1: Placental-derived Growth Factor (sFlt-1:PlGF)
A mean is taken for each patient with any daily value within 1-3 days, 4-7 days and 8-14 days. 
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 177 eligible 
115 did not want to be 
randomised 
62 randomised 
388 screened 
211 Ineligible 
30 allocated pravastatin 
Complete compliance n=21 
Partial compliance n=4 
Poor compliance n=0 
Rapid delivery n=5 
 
30 Live Births 
30 mothers and 
babies discharged 
from hospital 
2 neonatal deaths in 
severe pre-term babies 
  1 massive pulmonary 
haemorrhage at 2 days  
  1 sepsis at 8 days  
1 in utero death at 26 
weeks’ gestational age 
32 allocated placebo 
32 mothers and 29 
babies discharged 
from hospital 
31 Live Births 
Complete compliance n=21 
Partial compliance n=1 
Poor compliance n=3 
Rapid delivery n=7 
 
1 
Figure 2 Repeated measures analysis of s-FLT-1, PlGF and sFLT-1: PIGF during pregnancy and post-
randomisation, intention to treat analysis 
 
A: Soluble FMS-like tyrosine kinase-1 (sFlt-1) 
B: Placenta-derived Growth Factor (PlGF) 
C: Ratio Soluble FMS-like tyrosine kinase-1: Placenta-derived Growth Factor (sFlt-1:PlGF) 
A.       B.      C. 
  
Footnote: 
A mean is taken for each patient with any daily value within 1-3 days, 4-7 days and 8-14 days.  
Mean and 95% confidence intervals shown at each time-point. 
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